Literature DB >> 19344188

MicroRNA-based therapeutics for cancer.

Vivien Wang1, Wei Wu.   

Abstract

MicroRNAs (miRNAs) are non-protein-coding small RNA molecules that negatively regulate target messenger RNA through degradation or suppression of protein translation. MiRNAs play important roles in the control of many biologic processes, such as development, differentiation, proliferation, and apoptosis. Increasing evidence shows that aberrant miRNA expression profiles and unique miRNA signaling pathways are present in a variety of cancers. MiRNAs function as oncogenes or tumor suppressors during tumor development and progression. Experimental evidence demonstrates that correction of specific miRNA alterations using miRNA mimics or antagomirs can normalize the gene regulatory network and signaling pathways, and reverse the phenotype in cancerous cells. MiRNA-based gene therapy provides an attractive anti-tumor approach for integrated cancer therapy. In this review, we focus on miRNA-based treatment for cancers, summarize the delivery systems used in experimental and preclinical research, such as liposomes, viral vectors, and nanoparticles, and consider the safety and toxicity of miRNA therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19344188     DOI: 10.2165/00063030-200923010-00002

Source DB:  PubMed          Journal:  BioDrugs        ISSN: 1173-8804            Impact factor:   5.807


  67 in total

Review 1.  Evidence demonstrating role of microRNAs in the etiopathology of major depression.

Authors:  Yogesh Dwivedi
Journal:  J Chem Neuroanat       Date:  2011-04-14       Impact factor: 3.052

Review 2.  Targeting long non-coding RNA to therapeutically upregulate gene expression.

Authors:  Claes Wahlestedt
Journal:  Nat Rev Drug Discov       Date:  2013-06       Impact factor: 84.694

Review 3.  Prospects of miRNA-based therapy for pancreatic cancer.

Authors:  Priya Pai; Satyanarayana Rachagani; Chandrakanth Are; Surinder K Batra
Journal:  Curr Drug Targets       Date:  2013-09       Impact factor: 3.465

Review 4.  Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.

Authors:  Yujin Hoshida; Sara Toffanin; Anja Lachenmayer; Augusto Villanueva; Beatriz Minguez; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

5.  Altered expression of piRNAs and their relation with clinicopathologic features of breast cancer.

Authors:  G Huang; H Hu; X Xue; S Shen; E Gao; G Guo; X Shen; X Zhang
Journal:  Clin Transl Oncol       Date:  2012-11-15       Impact factor: 3.405

Review 6.  Clock genes: their role in colorectal cancer.

Authors:  Theodoros Karantanos; George Theodoropoulos; Dimitrios Pektasides; Maria Gazouli
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

Review 7.  MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Takatsugu Kan; Stephen J Meltzer
Journal:  Curr Opin Pharmacol       Date:  2009-09-19       Impact factor: 5.547

8.  Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells.

Authors:  Jie Yang; Yunxin Cao; Jifeng Sun; Yong Zhang
Journal:  Med Oncol       Date:  2009-11-12       Impact factor: 3.064

9.  MicroRNAs: exploring a new dimension in the pathogenesis of kidney cancer.

Authors:  Nicole M A White; George M Yousef
Journal:  BMC Med       Date:  2010-10-21       Impact factor: 8.775

10.  MicroRNA reexpression as differentiation therapy in cancer.

Authors:  Prasun J Mishra; Glenn Merlino
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.